TECH — BIO-TECHNE Corp
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 842023 ·
Last close
$54.00
Market Cap
$8.45B
52W High
$62.35
52W Low
$43.12
ADV30
3,336,460
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | 295,877,000 | 191,277,000 | 54,461,000 | 38,009,000 | 2,522,699,000 | 172,879,000 | 511,710,000 |
| Sep 2025 | 286,555,000 | 188,112,000 | 47,658,000 | 38,185,000 | 2,526,148,000 | 144,962,000 | 560,334,000 |
| Jun 2025 | 316,964,000 | 198,812,000 | 116,689,000 | -17,678,000 | 2,557,868,000 | 162,186,000 | 639,060,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$249,317,000
Investing CF
$-13,783,000
Financing CF
$-251,687,000
CapEx
$-26,297,000
Dividends Paid
$-49,881,000
Buybacks
$-200,127,000
EPS Diluted TTM
$0.69
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$1,106,819,000
Inventory
$205,447,000
Receivables
$184,614,000
ST Investments
—
EBIT TTM
$83,199,000
Pretax Income TTM
$75,916,000
Interest Exp TTM
$7,283,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,210,811,008
EBITDA
$366,044,992
Free Cash Flow
$299,849,376
Enterprise Value
$8,530,920,448
Total Cash
$214,114,000
Total Debt
$290,321,984
Shares Out
156,568,751
Trailing EPS
$0.70
Book Value
$12.90
ROE
5.3%
ROA
7.5%
Div Yield
0.59%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 1,219,635,000 | 242,804,000 | 73,400,000 | 2,557,868,000 | 639,060,000 | — | 287,556,000 |
| Jun 2024 | 1,159,060,000 | 246,401,000 | 168,105,000 | 2,703,867,000 | 635,017,000 | — | 298,981,000 |
| Jun 2023 | 1,136,702,000 | 290,998,000 | 285,263,000 | 2,638,692,000 | 672,176,000 | — | 254,393,000 |
| Jun 2022 | 1,105,599,000 | 295,828,000 | 272,051,000 | 2,294,805,000 | 593,794,000 | — | 325,272,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.06
Max Pain — expiry 2026-07-17
max pain strike: $55.00 · spot: $56.17 · call oi: 866 · put oi: 1,033
Expected Move to 2026-07-17:
±$6.18
(10.99%) —
implied range
$49.99 –
$62.34
· ATM straddle on $55.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HALO | HALOZYME THERAPEUTICS, INC. | $8.24B | $69.50 | — |
| QGEN | QIAGEN N.V. | $7.64B | $37.06 | — |
| KRYS | Krystal Biotech, Inc. | $9.37B | $317.97 | — |
| IBRX | ImmunityBio, Inc. | $7.44B | $7.10 | — |
| RGEN | REPLIGEN CORP | $7.37B | $130.59 | — |
News headlines (Yahoo Finance, 1h cache)
Piper Sandler Launches Coverage on Bio-Techne (TECH), Prefers Patience on Sector Growth Drivers
2026-06-15 05:03 · Yahoo
Is Bio-Techne Corporation (TECH) A Good Stock To Buy Now?
2026-06-13 20:43 · Yahoo
SpaceX initiated, Intel upgraded: Wall Street's top analyst calls
2026-06-11 13:38 · Yahoo
1 S&P 500 Stock with Impressive Fundamentals and 2 We Brush Off
2026-06-11 10:33 · Yahoo
New Bispecific Antibody Characterization Workflow Might Change The Case For Investing In Bio-Techne (TECH)
2026-06-08 21:19 · Yahoo
3 Reasons TECH is Risky and 1 Stock to Buy Instead
2026-06-08 17:17 · Yahoo
Why Is Techne (TECH) Up 4.5% Since Last Earnings Report?
2026-06-05 15:30 · Yahoo
Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization
2026-06-04 10:30 · Yahoo
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
2026-06-02 12:21 · Yahoo
Are Wall Street Analysts Bullish on Bio-Techne Stock?
2026-05-25 18:23 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.